Successful hip arthroplasty in an adult male with severe factor XI deficiency using Hemoleven ®, a factor XI concentrate

Haemophilia

Volumn 17, Issue 5, 2011, Pages 777-782

  Santoro, C ^a   Goldberg, I ^a   Bridey, F ^b   Figgie, M P ^c   Karila Israel, D ^d   Haviland, K ^a   Mackenzie, C R ^c   Dimichele, D M ^a,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b LFB BIOMEDICAMENTS   (France)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d ALTRAN EILIS   (France)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

FXI concentrate; Hemoleven ; Hip arthroplasty; Orthopaedic surgery; Severe FXI deficiency

Indexed keywords

BLOOD CLOTTING FACTOR 11 CONCENTRATE; BLOOD CLOTTING FACTOR 11 INHIBITOR; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR; D DIMER; DIPHENHYDRAMINE; ENOXAPARIN; FRESH FROZEN PLASMA; HEMOLEVEN; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING FACTOR 11 DEFICIENCY; CASE REPORT; CLINICAL PROTOCOL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEMOSTASIS; HIP ARTHROPLASTY; HUMAN; MALE; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; PREOPERATIVE THROMBOPHILIA; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOPHILIA;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD LOSS, SURGICAL; FACTOR XI; FACTOR XI DEFICIENCY; HEMOSTASIS, SURGICAL; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 80052035977     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02593.x     Document Type: Article

References (32)

1. Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82: 171-4.
2. Peyvandi F, Lak M, Mannucci PM. Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. Haematologica 2002; 87: 512-4.
3. Shpilberg O, Peretz H, Zivelin A et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995; 85: 429-32.
4. Seligsohn UJ. Factor XI deficiency in humans. Thromb Haemost 2009; 7(Suppl 1): 84-7.
5. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
6. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-8.
7. Bouma BN, Meijers JC. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol 2000; 7: 266-72.
8. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds - a clinical and laboratory study. Thromb Haemost 1995; 73: 194-202.
9. Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia 2008; 14: 1183-9.
10. Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12: 490-3.
11. Bolton-Maggs PH, Perry DJ, Chalmers EA et al. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
12. Bolton-Maggs PH, Wensley RT, Kernoff PB et al. Production and therapeutic use of a factor XI concentrate from plasma. Thromb Haemost 1992; 67: 314-9.
13. Burnouf Radosevich M, Burnouf T. A therapeutic, highly purified factor XI concentrate from human plasma. Transfusion 1992; 32: 861-7.
14. Smith JK. Factor XI deficiency and its management. Meeting at the Royal Free Hospital, London, 11 December 1995. Haemophilia 1996; 2: 128-36.
15. Mannucci PM, Bauer KA, Santagostino E et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84: 1314-9.
16. Goudemand J, Aurousseau MH, David B et al. A four-year experience of a pure factor XI concentrate. Haemophilia 1996; 2(Suppl 1): 13.
17. de Raucourt E, Aurousseau MH, Denninger MH, Verroust F, Goudemand M, Fischer AM. Use of a factor XI concentrate in three severe factor XI-deficient patients. Blood Coagul Fibrinolysis 1995; 6: 486-7.
18. Collins PW, Goldman E, Lilley P, Pasi KJ, Lee CA. Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate. Haemophilia 1995; 1: 227-31.
19. Lawler P, White B, Pye S et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8: 145-8.
20. Cobo Rodriguez T, Jimenez Yuste V, Chaves-Machado R, Villar-Camacho A, Quintana-Molina M, Hernandez-Navarro F. Factor XI (FXI) deficiency, single-centre experience in management of patients undergone to surgery under treatment with FXI concentrate (Hemoleven). Haemophilia 2004; 3: 5-13.
21. Duga S, Salomon O. Factor XI Deficiency. Semin Thromb Hemost 2009; 35: 416-25.
22. Bolton-Maggs PH. Factor XI deficiency and its management. Haemophilia 2000; 6(Suppl 1): 100-9.
23. Aledort LM, Forster A, Maksoud J, Isola L. BPL factor XI concentrate: clinical experience in the USA. Haemophilia 1997; 3: 59-62.
24. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997; 96: 293-7.
25. Salomon O, Zivelin A, Livnat T et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101: 4783-8.
26. Franchini M, Manzato F, Salvagno GL, Montagnana M, Lippi G. The use of desmopressin in congenital factor XI deficiency: a systematic review. Ann Hematol 2009; 88: 931-5.
27. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1: 307-17.
28. Musso R, Cultrera G, Giuffrida G, Fichera E, Di Francesco F, Salemi S. Recombinant activated factor VIIa as haemostatic agent in homozygous factor XI deficient patients. Thromb Haemost 2001; 6-12 July 2001 Paris, France. XVIII ISTH Congress (abstract P1133).
29. Billon S, Le Niger C, Escoffre-Barbe M, Vicariot M, Abgrall JF. The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12: 551-3.
30. O'Connell NM, Riddell AF, Pascoe G, Perry DJ, Lee CA. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia 2008; 14: 775-81.
31. Livnat T, Tamarin I, Mor Y et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102: 487-92.
32. Kenet G, Lubetsky A, Luboshitz J et al. Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors. Haemophilia 2009; 15: 1065-73.